Agenda for April 2026 Nephrology Advisory Committee meeting
Information on what the Nephrology Advisory Committee considered at its meeting in late April 2026.
Applications
The Committee discussed three items related to potassium citrate at a short online meeting.
Potassium citrate tablets
The Committee discussed a new formulation of potassium citrate, in a tablet form, for the treatment of recurrent calcium oxalate urolithiasis.
Widening access to other stone types
The Committee discussed widening access to potassium citrate for the treatment of recurrent kidney stones, to include other stone types and other changes to the criteria.
Widening access to hypercalciuria secondary to therapeutic ketogenic diet for specific conditions
The Committee discussed widening access to potassium citrate for the treatment of hypercalciuria, secondary to therapeutic ketogenic diet for epilepsy or other conditions.
Application for Potassium citrate tablets and widening access(external link)
Advisory meeting agenda setting
The scheduling and agenda setting process for advisory meetings considers multiple factors. We aim to balance the relative priorities of clinical advice needed across indications, the factors for consideration for each application (for example unmet health need), the time since applications were received and the internal and advisor resource available to support each meeting.